Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02554890 · ClinicalTrials.gov registry record · Phase 4
Comparison of Sacubitril/Valsartan Versus Enalapril on Effect on NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode.
A Phase 4 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 887
- Enrollment target
NCT02554890 is a Phase 4 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 887 participants.
The verdict
NCT02554890, a Phase 4 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 887 participants
- Enrollment target
Study Summary
The purpose of this study was to assess the effect of in-hospital initiation of sacubitril/valsartan (LCZ696) vs. enalapril on time averaged proportional change in NT-proBNP in patients who have been stabilized following hospitalization for acute decompensated heart failure (ADHF) and reduced ejection fraction (left ventricular ejection fraction (LVEF) ≤ 40%).
Interventions
- DRUG Enalapril
- DRUG sacubitril/valsartan (LCZ696)
- DRUG sacubitril/valsartan (LCZ696) matching placebo
- DRUG enalapril matching placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 887 participants |
| Start Date | 2016-04-29 |
| Est. Completion | 2018-07-24 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02554890
The ClinicalTrials.gov registry entry for NCT02554890 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 887 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Enalapril is the first listed.
NCT02554890 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02554890 about?
NCT02554890 is a clinical study titled "Comparison of Sacubitril/Valsartan Versus Enalapril on Effect on NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode.". The purpose of this study was to assess the effect of in-hospital initiation of sacubitril/valsartan (LCZ696) vs. enalapril on time averaged proportional change in NT-proBNP in patients who have been stabilized following hospitalization for acute decompensated heart failure (ADHF) and reduced ejecti...
What is the current status of trial NCT02554890?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 887 participants. The study started on 2016-04-29. Estimated completion is 2018-07-24.
What interventions are being tested in trial NCT02554890?
The interventions under investigation include: Enalapril (DRUG), sacubitril/valsartan (LCZ696) (DRUG), sacubitril/valsartan (LCZ696) matching placebo (DRUG), enalapril matching placebo (DRUG).
Who is sponsoring clinical trial NCT02554890?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.